In 2022, Wu et al. once again demonstrated that the TSH-TSHR Axis promotes tumor escape in thyroid cancer and glioma, indicating that TSH suppression therapy is an effective treatment strategy for immune checkpoint blockade combined therapy [89]. The gene discussed is TSHR; the disease is neoplasm.